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Abstract Elderly rheumatoid arthritis (RA) is classified
into two clinical subsets, elderly-onset RA (EORA) and
younger-onset elderly RA. With the improvement of life
expectancy in the general population and advent of the
super-aging society, the number of patients with EORA is
anticipated to increase. Both large and small joints are
affected initially at onset, and individuals with early EORA
have higher scores of disease activity and levels of acute-
phase reactants than those with early younger-onset RA.
EORA is a progressive disease similar to younger-onset
RA. Tumor necrosis factor (TNF) inhibitors are equally or
slightly less effective in elderly patients than in younger
patients with RA, and disease duration may have a greater
impact on disease outcomes than age. Evidence of non-
TNF biological disease-modifying antirheumatic drug use
in EORA is limited. TNF inhibitors may not increase the
risk for infection in elderly patients any more than
methotrexate; however, increasing age is an independent
and strong risk factor for serious infections in patients with
RA. Treatment choice in patients with EORA is strongly
influenced by comorbidities, especially cardiovascular
disease, chronic lung disease, and frailty. To prevent pro-
gression to irreversible geriatric syndromes, non-frail
patients with EORA, who are aging successfully should
undergo intensive treatment using the treat-to-target
strategy, and pre-frail and frail patients with EORA should
be treated with the aim of returning to a non-frail or pre-
frail stage, respectively. An appropriate treatment strategy
for EORA and younger-onset elderly RA should be
developed in the next decade using a multi-disciplinary
approach.
Key Points
The growing number of patients with elderly-onset
rheumatoid arthritis and younger-onset elderly
rheumatoid arthritis poses a challenge to the clinical
practice of rheumatology in the super-aging
societies.
Biological disease-modifying antirheumatic drugs
are indispensable in the treatment of patients with
elderly-onset rheumatoid arthritis.
An evidence-based treatment strategy for this patient
population should be established in the next decade
with special emphasis on the benefit-risk balance of
various treatments.
1 Introduction
Over the past decade, the clinical development and
approval of various types of biological disease-modifying
antirheumatic drugs (bDMARDs) along with new classifi-
cation criteria [1] and a novel treatment strategy has
brought about tremendous changes in the outcomes of
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treatment for rheumatoid arthritis (RA). Early diagnosis
and immediate initiation of treatment with conventional
synthetic DMARDs (csDMARDs), primarily methotrexate
(MTX), constitute the mainstream treatment for middle-
aged patients with RA. Treating RA to target is a consensus
strategy in this population [2, 3]; prospective cohort studies
and randomized controlled trials (RCTs) showed that
aiming at remission or low disease activity (LDA) by
strategic switching of DMARDs is a realistic and practi-
cable approach in patients with RA [4–7] and conveys
better outcomes than routine care [8].
In the treatment of RA with treat-to-target strategy,
bDMARDs are indispensable. The European League
against Rheumatism (EULAR) Task Force recommended
that in patients responding insufficiently to MTX and/or
other csDMARDs, with or without glucocorticoids, a
bDMARD [tumor necrosis factor (TNF) inhibitor, T-cell
costimulation inhibitor or interleukin-6 receptor-blocking
monoclonal antibody, and under certain circumstances,
anti-B-cell agent] should be commenced [9]. A 2014
update of recommendations on treating RA to target
emphasized that the choice of the composite measure of
disease activity and the target value is influenced by
comorbidities, patient factors, and drug-related risks [3].
Such influencing factors are frequently observed in patients
with elderly RA, which makes treatment of this patient
population very challenging. In this article, we review the
clinical features of elderly-onset RA (EORA), effective-
ness and safety of bDMARDs in elderly RA, and obstacles
that prevent rheumatologists from providing standard
treatment to EORA patients as well as the countermea-
sures, and discuss priorities for future research in this
growing field of rheumatology.
2 EORA
2.1 Definition
Elderly RA is categorized into two clinical subsets; EORA
and younger-onset elderly RA [10]. Onset after 60 years of
age is mainly adopted as the classical definition of EORA
in the literature. This definition of EORA has been used
throughout this review unless otherwise specified, although
we recognize that elderly individuals are generally
healthier in the current aging society than ever and the
definition of elderly-onset should be validated or modified
in future.
2.2 Epidemiology
Previous epidemiological studies showed a declining trend
in the incidence rates of RA in the period 1955–1994 [11].
However, the incidence rate of EORA (age[64 years)
increased from 1980 to 2000 [12]. Recent epidemiological
studies in Minnesota showed an increasing trend in the
incidence rates of RA from 1995 to 2007 in women of each
age category [13]. The incidence rates of RA in the
1995–2007 period were highest in individuals aged
65–74 years and decreased over the age of 75 years. The
cumulative risk of RA rose sharply around 60 years of age
[14]. A recent large RA registry in the United States
showed that approximately one-fourth of the enrolled
patients were diagnosed with EORA after the age of
60 years [15, 16]. In a Swiss prospective observational
cohort for early RA and undifferentiated arthritis (disease
duration after the first symptom B1 year), the age at dis-
ease onset had a Gaussian distribution with a single peak
between 50 and 60 years and was C60 years in 38.2 % of
the 592 patients [17]. Because life expectancy has
increased in the general population and people
aged C65 years account for the fastest-growing population
in industrialized countries, the number of patients with
EORA will definitely increase over the next decade.
2.3 Clinical Features
Various investigators have reported the clinical features of
EORA. Both large and small joints are affected more fre-
quently initially at onset, and serological tests show equal
or slightly lower percentage of positivity of rheumatoid
factor (RF) and anti-cyclic citrullinated peptide (anti-CCP)
antibody in individuals with early EORA than in those with
early younger-onset RA [10, 18–20]. Individuals with early
EORA have higher disease activity scores, erythrocyte
sedimentation rates, and C-reactive protein levels than
early younger-onset RA [10, 18]. An explosive onset of
shoulder arthritis, resembling polymyalgia rheumatica
(PMR) is observed in 13–23 % of patients with early
EORA [10, 18, 19]. Differentiation between anti-CCP
antibody-negative EORA with PMR-like onset and PMR
can be difficult and requires careful follow-up [21].
3 Effectiveness of bDMARDs in Elderly RA
Several large cohort studies (British, Danish, Dutch, Ital-
ian, Spanish, and Swiss registries) investigated the asso-
ciation between treatment response and age [22–27]. TNF
inhibitors were slightly less or equally effective in reducing
disease activity in elderly individuals compared with
younger individuals (Table 1). Health assessment ques-
tionnaire (HAQ) scores improved less in elderly RA,
especially in patients aged[75 years [22, 23, 26]. How-
ever, the vast majority of these patients had longstanding
disease, and the proportions of EORA patients in the study
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Table 1 Influence of age on the treatment response to biological DMARDs
Study Age and disease
duration in the
elderly age group
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Similar improvement in ACR20 and ACR50
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and physical function; higher discontinuation
rate because of adverse events
RA rheumatoid arthritis, RCT randomized controlled trial, IFX infliximab, MTX methotrexate, ETN etanercept, ADA adalimumab, TCZ tocili-
zumab, TOF tofacitinib, EORA elderly-onset rheumatoid arthritis, SDAI Simplified Disease Activity Index, DAS28 Disease Activity Score in 28
Joints, HAQ Health Assessment Questionnaire, DMARDs disease-modifying antirheumatic drugs, ACR20 American College of Rheumatology
20 % improvement criteria, ACR50 American College of Rheumatology 50 % improvement criteria, ACR70 American College of Rheumatology
70 % improvement criteria
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populations were not specified. Because chronic inflam-
mation and subsequent joint destruction owing to RA have
a negative impact on physical function as well as the
development of comorbidities, the effectiveness of treat-
ment in EORA and younger-onset elderly RA should be
investigated separately.
Post hoc analyses of RCTs showed efficacy of TNF
inhibitors (etanercept, infliximab, or adalimumab) in elderly
patients with early RA who were presumably diagnosed
with EORA [15, 28, 29]. Combination of a TNF inhibitor
and MTX was more effective in improving signs and
symptoms of RA and physical function and in reducing joint
damage in elderly patients with early RA compared with
MTX monotherapy [15, 28]. In addition, the efficacy was
similar across all age groups in contrast to the results of
large cohort studies that enrolled patients with longstanding
RA. These results indicated that disease duration may have
a greater impact on disease outcomes than onset age. Kor-
ean observational cohort also showed that disease dura-
tion C10 years as well as older age (C40 years) was
associated with HAQ disability index[1, but onset age was
not. After stratification of the patients by disease duration,
onset age C60 years was associated with HAQ disability
index[1 in patients with disease duration\10 years [30].
The evidence for effectiveness of tocilizumab, abata-
cept, rituximab, and tofacitinib in elderly RA is scarce. In a
French registry, 61 (27.5 %) of 222 RA patients treated
with tocilizumab were aged C65 years at treatment initia-
tion. Tocilizumab was less effective in the elderly group
[31], and the drug retention rate for tocilizumab and dis-
continuation rates because of adverse events were similar
between the two age groups, i.e., under 65 years and over
65 years [32]. Data on abatacept in elderly RA were not
published. Post hoc analyses of RCTs showed tofacitinib to
be similarly efficacious in both the elderly and non-elderly
groups (Table 1) [33].
Because a substantial number of patients with EORA
have comorbidities or health-related problems that pre-
clude them from participating in RCTs, a prospective,
multicenter large cohort study is required to evaluate the
effectiveness and safety of treatment with bDMARDs in
patients with EORA.
4 Safety of bDMARDs in Elderly Patients with RA
4.1 Overall Safety
Clinical trials and biologic registries identified the char-
acteristics of adverse drug reactions (ADRs) of bDMARDs.
The main ADRs common to all bDMARDs in patients with
RA in general are systemic disorders and administration-
site conditions, infection and infestations, nervous system
disorders, respiratory, thoracic, and mediastinal disorders,
and skin and subcutaneous tissue disorders [34–38].
Among these, infection and infestation and thoracic and
mediastinal disorders are usually at the top of the list of
serious ADRs with high incidence rates in patients
receiving bDMARDs. In addition, malignancy, blood and
lymphatic system disorders, immune system disorders, and
gastrointestinal perforation, although less common, are
considerable ADRs during treatment with bDMARDs.
Several studies have reported the overall safety of
bDMARDs in elderly patients compared with younger
patients. Sub-analyses of RCTs showed comparable inci-
dence rates of adverse events between patients aged\65
and C65 years [28, 39, 40]. Some observational studies
indicated an increased risk for adverse events or infections
in elderly patients treated with TNF inhibitors compared
with younger patients [26, 41], while other studies reported
a similar safety profile between the two groups of patients
[22, 42]. Such discrepancies could arise from differences in
study design, study population, types of events analyzed,
length of observation period, and statistical methods.
4.2 Risk of Infection in Elderly Patients with RA
Population-based studies showed that patients with RA are
more susceptible to infection compared with non-RA
individuals [43–45]. Hazard ratios (HRs) of infection in
patients with RA were between 1.45 and 1.83, depending
on the definition of infections [44], and the risk ratio of
hospitalized infection in patients with RA or psoriatic
arthritis was 2.7 compared with non-RA population [45].
Older age was a significant risk factor of infection or
serious infection in patients with RA [43, 46]. A study
using health administrative data of people aged C66 years
in Canada showed that the most frequently occurring
events included respiratory infections, herpes zoster, and
skin/soft-tissue infections. Higher comorbidity, rural resi-
dence, markers of disease severity, history of previous
infection, and use of glucocorticoids, TNF inhibitors, and
some DMARDs or immunosuppressants were significant
risk factors of serious infection [47]. In regard to the risk of
serious infection associated with the use of oral glucocor-
ticoids in older patients (C65 years of age) with RA, the
current and recent doses have the highest impact on current
risk, but doses taken up to 2.5 years ago are also associated
with increased current risk [48]. Use of glucocorticoids
doubled the incidence rates of serious bacterial infections
in Medicare beneficiaries aged C65 years with RA, with
clear dose-response relationships and more impact during
1–90 days after treatment initiation compared with[90 -
days [49]. These data indicate that infection is the primary
concern in elderly patients with RA, who are initiating
treatment with bDMARDs.
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Observational studies comparing RA patients who used
TNF inhibitors and conventional DMARDs showed
increasing age as an independent risk factor for serious
infections [50–52]. This was also the case with pneumonia
in patients who were given infliximab [34] as well as
serious infection in patients given etanercept [38], adali-
mumab [53], or tocilizumab [54] in the all-cases post-
marketing surveillance programs implemented in Japan.
Although the crude rate of infection increased markedly
with increasing age in the group starting TNF inhibitors
and that starting conventional DMARDs, the adjusted HR
of the TNF inhibitor group vs the conventional DMARDs
group was similar across the age groups [52]. Similarly, no
increase in the risk of serious bacterial infections was
observed among the initiators of TNF inhibitors in elderly
patients with RA compared with initiators of MTX after
adjusting for covariates [49]. There is not enough evidence
for the safety of non-TNF bDMARDs in elderly patients
with RA including EORA. An analysis of the Medicare
claims database of patients with RA revealed the compar-
ative risk of hospitalized infection during treatment with
various bDMARDs. Patients aged C65 years accounted for
*30 to 50 % of the patient population in this study. The
overall incidence rate of hospitalized infection was 15.3/
100 patient-years. After adjusting for infection risk score
and other potential confounders, infliximab (HR 1.39,
95 % CI 1.21–1.53), rituximab (HR 1.36, 95 % CI
1.21–1.53), and etanercept (HR 1.24, 95 % CI 1.07–1.45)
users had a significantly higher hazard of hospitalized
infection compared with abatacept users [55].
5 Challenges in Treatment Targeting LDA
in Patients with EORA
In clinical practice, patients with EORA often have age-,
RA-, or treatment-related comorbidities, and these condi-
tions strongly influence the treatment choice. Such
comorbidities include cardiovascular disease, cerebrovas-
cular disease, interstitial lung disease (ILD), chronic
obstructive pulmonary disease, chronic kidney disease,
peptic ulcer, diabetes mellitus, anemia, cachexia, cancer,
osteoporosis, osteoarthritis, sarcopenia, skin ulceration,
depression, cognitive impairment, and infection. As these
diseases are multi-factorial and mutually related, the term
‘‘multi-morbidity’’ instead of comorbidity has recently
been proposed to describe them [56].
5.1 Cardiovascular Disease
Atherosclerosis is a common age-related comorbidity and
an important RA-related comorbidity among patients with
RA. Various studies have demonstrated the risk of car-
diovascular disease in RA populations [57–60]. An obser-
vational study of the registry of North America found that
coronary artery disease, myocardial infarction, stroke, and
hypertension were more common among individuals with
EORA (mean disease duration; 5.3 years) compared with
disease duration-matched individuals with younger-onset
non-elderly RA [16]. Interestingly, a Swedish cohort of
early RA showed differential risks for cardiovascular
events and mortality through 10 years between patients
with RA with disease onset before 65 years and after
65 years of age. In the elderly-onset population ([65 years
of age), good disease control in terms of disease activity
and physical function reduced cardiovascular event risk,
and the use of glucocorticoids resulted in more cardio-
vascular events and poorer survival [61]. In the non-
elderly-onset population (B65 years of age), inadequate
control of inflammation and presence of RF or the anti-
CCP antibody were associated with cardiovascular events.
These findings are in line with the report that the risk for
myocardial infarction was reduced in middle-aged patients
with RA who responded well to TNF inhibitors [62].
According to the EULAR Task Force, patients with RA-
related comorbidities such as cardiovascular disease may
undergo intensive treatment [3]. This may be the case with
EORA, but further investigation is required to establish an
appropriate management strategy.
5.2 ILD
ILD is an extra-articular manifestation of RA, and is
associated with mortality [63, 64]. Existence of ILD should
be examined before treating patients with EORA, as the
age at the time of diagnosis of RA was a risk factor for the
development of ILD in a Mayo Clinic cohort (HR: 1.41 per
10-year increment in age, 95 % CI 1.11–1.79) [64]. This
study showed that the risk for death in RA patients with
ILD was three times higher than in RA patients without
ILD. The median survival after the ILD diagnosis was only
2.6 years. The British Society for Rheumatology Biologics
Register also showed that patients with RA-associated ILD
were older than those without ILD [65]. A prospective
monocentric Japanese registry of EORA (Choju registry of
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rheumatoid arthritis treated with non-biologic disease-
modifying antirheumatic drugs and biologics in elderly
patients in Japan [CRANE]; ‘‘Choju’’ is a Japanese word
meaning longevity) found that pre-existing ILD was
observed in 25 (16.6 %) of 151 patients with EORA; RA-
associated ILD deteriorated over a relatively short period in
4 of the 25 patients and one patient without pre-existing
ILD developed organizing pneumonia and pleuritis. All
five patients were receiving csDMARDs and had high
disease activity when ILD worsened; 0.5–1 mg/kg/day of
prednisolone (PSL) was administered, and four patients
recovered, but one died of exacerbation of ILD at week 28
of the observation period [66]. The presence of ILD has
significant impact on mortality of patients with RA. Res-
piratory diseases and malignancy were two major causes of
death followed by cardiovascular diseases in a large
Japanese cohort. Pneumonia and ILD accounted for 50 and
46 % of the respiratory diseases, respectively [67].
Treatment with bDMARDs in RA patients with ILD is
challenging. In patients with RA-associated ILD, mortality
following treatment with anti-TNF therapy is not higher
than that with traditional DMARDs [65]. However, chronic
lung diseases including ILD is a well-established risk
factor of infection in patients with RA [46, 51]. Rheuma-
tologists sometimes hesitate to use MTX in patients with
RA with ILD, and treatment with glucocorticoids is com-
menced. Coexistence of chronic lung diseases, older age,
and concomitant use of glucocorticoids can further increase
risk for infection or serious infection. Hence, the benefit-
risk balance of bDMARDs in patients with ILD should be
evaluated carefully before starting treatment [50, 68].
5.3 Frailty
Frailty is a key concept in geriatric medicine and com-
monly occurs in older adults [69]. The common definition
of frailty uses five criteria, which include weight loss (or
loss of muscle), slow walking speed, exhaustion (or fati-
gue), muscle weakness, and low levels of physical activity.
Patients are considered frail if three or more of the five
criteria are met. Patients with a score of 1 or 2 are con-
sidered to be pre-frail, and a score of 0 indicates that the
person is robust or not frail [70]. There are differences in
the social, psychological, and physical functioning levels
of elderly patients among the three stages of frailty [71].
Various chronic diseases including osteoarthritis, pul-
monary disease, cardiovascular disease, stroke, chronic
kidney disease, sarcopenia (the age-related loss of skeletal
muscle mass), depression, and cognitive impairment are
major risk factors of frailty [72–74]. Frail individuals are at
an increased risk for negative health outcomes such as
functional decline, falls, institutionalization, pressure
ulcers, delirium, incontinence, malnutrition, and mortality
(Fig. 1). Although the impact of frailty on mortality of
elderly patients with RA is unclear, a recent observational
study for patients with osteoarthritis showed that frailty and
related geriatric syndromes (i.e., disability of daily living,
poor morbidity, visual impairment, cognitive impairment,
hearing impairment, urinary incontinence, and low social
support) enhanced the risk for long-term mortality of
elderly patients [75].
Patients with advanced elderly RA are at a higher risk
for progression to frailty because they are more likely to
have functional decline, depression, cognitive impairment,
falls, malnutrition, and polypharmacy [76–81]. To prevent
progression to irreversible geriatric syndromes, non-frail
patients with EORA, who are aging successfully, should
undergo intensive treatment using the treat-to-target strat-
egy, and pre-frail and frail patients with EORA should be
treated with the aim of returning to a non-frail or pre-frail
stage, respectively (Fig. 1). Physical exercise may be also
an important aspect of treatment strategy of EORA to
facilitate maintaining functional capacity in daily life
because it provided various beneficial effects including
increase of muscle strength, maintenance of normal bone
mineral density, and reduced risk of cardiovascular disease
in patients with non-elderly RA [82–85]. However, treating
frail patients is usually difficult and complicated because
they commonly have a variety of age-, RA-, and treatment-
related comorbidities and are prone to progress to an irre-
versible stage of disability. In addition, physicians should
avoid polypharmacy in this clinical setting because a
number of potentially inappropriate medications may
induce ADR, drug–drug interactions, and nonadherence in
older adults and are associated with serious problems such
as delirium, gastrointestinal bleeding, falls, and fracture
[86–89].
6 Role of bDMARDs in Treatment Targeting LDA
in EORA
Previous prospective studies showed that patients with
EORA had a prognosis as poor as those with younger-onset
non-elderly RA in terms of radiographic progression and
physical disability [17, 18]. Anti-CCP antibodies, RF,
baseline disease activity, baseline erosion score, and HLA-
DR4 positivity were risk factors of joint destruction in
patients with EORA [17–19], and these findings are in
overall agreement with previous reports of the predictors of
joint destruction in non-elderly RA populations [90–93].
Interestingly, no response by EULAR response criteria at
week 12 and non-achievement of LDA at week 24 were
both strongly associated with progression of joint
destruction at 1 year in patients with EORA receiving
treatment targeting LDA [66]. Because rapid improvement
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of disease activity by treatment with bDMARDs reduces
the risk for joint destruction in patients with poor prog-
nostic features [90, 92, 94, 95], optimal management of
EORA requires intensive treatment including bDMARDs
with a careful evaluation of risks for serious adverse
events, especially serious infections.
Even though previous studies clearly showed that EORA
is a progressive disease similar to younger-onset non-
elderly RA, increasing age has been found to be a deter-
minant of less intensive RA care in clinical practice [96,
97]. Biological DMARDs were used less frequently in
patients with EORA (EORA 25 % vs younger-onset non-
elderly RA 33.1 %), whereas use of glucocorticoids in
patients with EORA was slightly higher (EORA 41 % vs
younger-onset non-elderly RA 37.6 %) than that in patients
with younger-onset non-elderly RA [16]. A similar obser-
vation was reported from a Swiss cohort: bDMARDs were
used in 6.6 % of patients with EORA and 14.1 % of patients
with younger-onset non-elderly RA; glucocorticoids were
used in 68 % of patients with EORA and 25 % of patients
with younger-onset non-elderly RA [17]. Intensive therapy
with bDMARDs may be avoided under the assumption that
it is not required in patients with EORA. Furthermore, older
age, comorbidities, patient factors, and treatment-related
risks may preclude the intensification of therapy targeting
LDA or remission in patients with EORA.
Although remission should be the primary treatment
target for early RA, LDA can be an alternative and valid
treatment target in patients with early EORA [3]. Our
prospective observational study [66] showed that achieving
LDA and structural and functional remission were realistic
goals for patients with EORA. In this study, we intensified
the treatment as scheduled in advance to achieve LDA.
Adherence to the treat-to-target strategy was possible in
83.4 % of the 151 patients at week 24 and in 75.5 % at
week 52, and 32.4 % of the patients were receiving
bDMARDs at week 52.
Combination therapy with a high dose of MTX and low
dose of PSL, with or without other csDMARDs is as
effective as biological DMARDs plus MTX to prevent
disease progression in middle-aged patients with RA.
A Dutch treat-to-target cohort with a mean age of
58.6 years showed that 85.5 % of patients who achieved
sustained remission were treated with csDMARDs alone.
Nevertheless, bDMARDs may have a major role in the
treat-to-target strategy of EORA because longstanding use
of PSL and a high dose of MTX may be intolerable or may
be associated with serious ADRs in elderly patients. PSL is
strongly associated with serious infection in the elderly or
EORA population [47, 49, 66]. In our EORA cohort
(CRANE), the majority of the elderly patients could not
receive the maximum dosage of MTX because of renal
dysfunction or dose-dependent ADRs of MTX [66]. The
average dose of MTX was 8.9 ± 2.6 mg/week
(0.17 ± 0.06 mg/kg/week, average weight 51.6 kg) in the
CRANE cohort. In an American registry, use of MTX is
common in patients with EORA; however, the average
MTX dose (11.96 mg/week, average weight 74.6 kg) in the
EORA population is lower than that in the younger-onset
RA population [16]. Concomitant MTX is associated with
improved retention rates of bDMARDs, particularly TNF
inhibitors, in the elderly RA Medicare population [98].
Because a low dose of MTX (10 mg/week) plus adali-
mumab is sufficient to achieve LDA or functional remis-
sion [99], this regimen without PSL may be a realistic
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Fig. 1 Various chronic diseases
including rheumatoid arthritis
(RA) are major risk factors of
frailty. Frail individuals are at
an increased risk for developing
irreversible geriatric syndromes.
An important treatment target
for patients with elderly-onset
rheumatoid arthritis (EORA) is
to achieve a non-frail condition.
A non-frail condition is a
challenging target to achieve in
patients with advanced-stage
EORA or EORA with severe
comorbidities. Preventing
progression to irreversible
geriatric syndromes may be a
major treatment target in these
patients
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7 Agenda of Future Clinical Research
We have drafted a preliminary research agenda for current
and future roles of bDMARDs in patients with EORA.
• Prospective and multicentric collection of data on the
effectiveness and safety of bDMARDs in patients with
EORA and younger-onset elderly RA incorporating
treatment intensification targeting LDA or remission.
The data should be separately evaluated and compared
between patients with EORA and younger-onset elderly
RA.
• Evaluation of the impact of frailty and multi-morbidity
on disease outcomes in patients with EORA or
younger-onset elderly RA treated with biologics.
• Determination of treatment targets in patients with
EORA and younger-onset elderly RA with optimal
benefit-risk balance.
• Analysis of data of patients with elderly RA from
ongoing cohort studies of tocilizumab, abatacept,
rituximab, or tofacitinib.
• Establishment of treatment strategy for early EORA
with comparative assessment of benefit-risk balance
across MTX monotherapy, bDMARDs, PSL, and
combination therapy of MTX and other csDMARDs.
8 Conclusion
The treat-to-target strategy and role of bDMARDs have
been established in middle-aged patients with RA. In the
next decade, a strategy suitable for patients with EORA or
younger-onset elderly RA should be developed because
the number of these patients is on the rise. TNF inhibitors
are slightly less or equally effective in reducing disease
activity in elderly patients with RA than in younger
patients, and disease duration may have a greater impact
on disease outcomes than age. Achieving LDA and
structural and functional remission are realistic goals in
patients with relatively early EORA. With regard to
safety, observational studies show increasing age as an
independent risk factor for serious infections, and infec-
tion is the primary concern in elderly patients with RA,
who are initiating treatment with bDMARDs. Cardiovas-
cular disease, chronic lung diseases, and frailty are
common problems in the treatment of patients with
elderly RA. Multi-morbidities, frailty, and treatment-re-
lated risks make it difficult to establish a treatment
strategy for EORA, but these issues must be resolved
using a multi-disciplinary approach to address the ongo-
ing challenge in the super-aging society.
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